USANA Health Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Summary Of Significant Accounting Policies (Tables)

Summary Of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 28, 2019

Summary Of Significant Accounting Policies [Abstract]

Schedule Of Assets And Liabilities Measured At Fair Value



			Fair Value Measurements Using
	December 28,		Inputs
	2019		Level 1		Level 2		Level 3
Money market funds included in cash equivalents	$	180,032	$	180,032	$	—	$	—
Foreign currency contracts included in other current liabilities		(764)		—		(764)		—
	$	179,268	$	180,032	$	(764)	$	—

			Fair Value Measurements Using
	December 29,		Inputs
	2018		Level 1		Level 2		Level 3
Money market funds included in cash equivalents	$	129,449	$	129,449	$	—	$	—
Foreign currency contracts included in other current liabilities		(309)		—		(309)		—
	$	129,140	$	129,449	$	(309)	$	—

Schedule Of Contract Liabilities From Contract With Customers



	December 28,		December 29,
	2019		2018
Contract liabilities at beginning of period	$	15,055	$	14,417
Increase due to deferral of revenue at period end		13,852		15,055
Decrease due to beginning contract liabilities recognized as revenue		(15,055)		(14,417)
Contract liabilities at end of period	$	13,852	$	15,055

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details